WEBINAR RECORDING AVAILABLE - WATCH ON DEMAND

Accelerating first-in-class and best-in-class programs using a large-scale digital chemistry strategy

Drug discovery organizations across the globe are seeking to accelerate the rate at which they bring safe, effective therapeutics to patients. Yet the bar for clinical compounds remains high as competitive landscapes become crowded and easily druggable targets have been targeted. The most innovative companies are modernizing their R&D organizations with digital solutions that leverage the combined power of large-scale computational workflows and their own team’s scientific expertise to identify higher quality molecules more rapidly. In this webinar, you’ll learn how a large-scale collaborative digital chemistry strategy is accelerating first-in-class and best-in-class programs across a range of target classes.

Key topics covered:

How the foundational elements of a digital chemistry strategy for molecular design, discovery, and collaboration lead to more efficient design-make-test cycles
Strategies for approaching first-in-class and best-in-class programs using structurally enabled computationally-powered workflows
Case studies from Schrödinger and Morphic Therapeutic demonstrating the impact on programs from hit identification through lead optimization

watch now

Aleksey Gerasyuto

Vice President, Drug Discovery, Early Stage Portfolio Lead, Schrödinger

Dr. Gerasyuto is a seasoned drug hunter with extensive experience in computationally-driven drug discovery. In his current role at Schrödinger, Dr. Gerasyuto is responsible for Medicinal Chemistry of Early Stage Portfolio and co-leads multidisciplinary efforts to shape the Drug Discovery Team’s internal and collaborative pipeline. He has contributed to the establishment of several successful and productive collaborations including with Morphic Therapeutic, Petra Pharma, BMS and Zai Lab. Prior to joining Schrödinger, Dr. Gerasyuto worked at PTC Therapeutics, one of the pioneers of targeting RNA biology with small molecules. Dr. Gerasyuto contributed to the discovery of several clinical candidates including PTC518 for Huntington disease (Phase 2), MORF-057 for ulcerative colitis (Phase 2) and LOXO-783 for breast cancer and other solid tumors (Phase 1). Dr. Gerasyuto received his Ph.D. from University of Wisconsin, Madison and B.S./M.S. from Higher Chemical College of Russian Academy of Sciences.

Matthew Bursavich

Vice President, Head of Chemistry, Morphic Therapeutic

Dr. Bursavich, Ph.D., is a drug discovery leader with 20 years of experience at pharmaceutical, biotech, and start-up companies including Wyeth, FORUM Pharmaceuticals and Morphic Therapeutic. As the Morphic head of chemistry, he is responsible for an expanding portfolio of integrin-based drug discovery efforts. During his career as a medicinal chemist, Matt has >40 published papers and 39 granted or published patents and applications. He has led teams to the discovery of multiple compounds progressing into development, including FRM-024 at FORUM for familial Alzheimer’s Disease and MORF-057 at Morphic, currently in Phase 2 trials for Ulcerative Colitis. Matt obtained his Ph.D. in Organic Chemistry from the University of Wisconsin-Madison and a B.S in Chemistry from Louisiana State University.

moderator

Arsalan Arif

Founder & publisher, endpoints news

Arsalan Arif is a news media entrepreneur who set out in 2015 to build his vision of an independent biotech news company at Endpoints News.